Everolimus in liver and lung transplantation

Drugs of Today

Volumn 45, Issue 1, 2009, Pages 21-31

  Koch, Martina ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RAPAMYCIN;

ACUTE GRAFT REJECTION; ARTICLE; BACTERIAL INFECTION; CHOLESTEROL BLOOD LEVEL; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG GRAFT REJECTION; LUNG TOXICITY; LUNG TRANSPLANTATION; MALIGNANT NEOPLASTIC DISEASE; MYCOSIS; NEPHROTOXICITY; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WOUND HEALING IMPAIRMENT;

EID: 63449141124     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. The Eurotransplant International Foundation. Available at: http://www.eurotransplant.nl/files/annual-report/ AR2007. Accessed February 16, 2009.
2. Chapman, J.R., Webster, A.C. Cancer after renal transplantation: The next challenge Am J Transplant 2004, 4(6): 841-2.
3. Kasiske, B.L., Snyder, J.J., Gilbertson, D.T., Wang, C. Cancer after kidney transplantation in the United States. Am J Transplant 2004 4(6): 905-13.
4. Kessler, M., Jay, N., Molle, R., Guillemin, F. Excess risk of cancer in renal transplant patients. Transpl Int 2006,19(11): 908-14.
5. Hussar, D.A. New drugs of 1999. J Am Pharm Assoc (Wash) 2000, 40(2): 181-221; guiz 323-7.
6. Schuler, W., Sedrani, R., Cottens, S. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo. Transplantation 1997, 64(1): 36-42.
7. Vilella-Bach, M, Nuzzi, P., Fang, Y., Chen, J. The FKBP12- rapamycin-binding domain is required for FKBP12- rapamycin-associated protein kinase activity and CI progression. J Biol Chem 1999, 274(7): 4266-72.
8. Nashan, B. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs 2002,11(12): 1845-57.
9. Calne, R.Y., Collier, D.S., Lim, S. et al. Rapamycin for immunosuppression in organ allografting. Lancet 1989, 2(8656): 227.
10. Chapman, J.R., Valantine, H., Albanell, J. et al. Proliferation signal inhibitors in transplantation: Questions at the cutting edge of everolimus therapy. Transplant Proc 2007, 39(10): 2937-50.
11. Bohler, T., Weiser, J., Budde, K. et al. The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation. Transplant Proc 1998, 30(5): 2195-7.
12. Kim, M.S., Park, J., Ha, H. et al. Rapamycin inhibits platelet- derived growth factor-induced collagen, but not fibronectin, synthesis in rat mesangial cells. Yonsei Med J 2004, 45(6): 1121-6.
13. Schuurman, H.J., Pally, C., Weckbecker, G., Schuler, W., Bruns, C. SDZ RAD inhibits cold ischemia-induced vascular remodeling. Transplant Proc 1999, 31(1-2): 1024-5.
14. Lutz, J., Zou, H., Liu, S., Antus, B., Heemann, U. Apoptosis and treatment of chronic allograft nephropathy with everolimus. Transplantation 2003, 76(3): 508-15.
15. Schuurman, H.J., Cottens, S., Fuchs, S. et al. SDZ RAD, a new rapamycin derivative: Synergism with cyclosporine. Transplantation 1997, 64(1): 32-5.
16. Schuurman, H.J., Ringers, J., Schuler, W., Slingerland, W., Jonker, M. Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation. Transplantation 2000, 69(5): 737-42.
17. Viklický, O., Zou, H., Muller, V., Lacha, J., Szabó, A., Heemann, U. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 2000, 69(4): 497-502.
18. Koch, M., Mengel, M., Poehnert, D., Nashan, B. Effects of everolimus on cellular and humoral immune processes leading to chronic allograft nephropathy in a rat model with sensitized recipients. Transplantation 2007, 83(4): 498-505.
19. Cole, O.J., Shehata, M., Rigg, K.M. Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. Transplant Proc 1998, 30(5): 2200-3.
20. Salminen, U.S., Maasilta, P.K., Taskinen, E.I., Alho, H.S., Ikonen, T.S., Harjula, A.L. Prevention of small airway obliteration in a swine heterotopic lung allograft model. J Heart Lung Transplant 2000,19(2): 193-206.
21. Lorber, M.I., Mulgaonkar, S., Butt, K.M. et al.; B251 Study Group. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: A 3-year randomized, multicenter, phase III study. Transplantation 2005, 80(2): 244-52.
22. Vitko, S., Margreiter, R., Weimar, W. et al.; RAD B201 Study Group. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005, 5(10): 2521-30.
23. Viganò, M., Tuzcu, M., Benza, R. et al.; RAD B253 Study Group. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplant recipients: A 24- month analysis. J Heart Lung Transplant 2007, 26(6): 584-592.
24. Eisen, H.J., Tuzcu, E.M., Dorent, R. et al.; RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003, 349(9): 847-58.
25. Nashan, B., Curtis, 1, Ponticelli, C, Mourad, G., Jaffe, J., Haas, T.; 156 Study Group. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: A three- year phase II, randomized, multicenter, open-label study. Transplantation 2004, 78(9): 1332-40.
26. Kauffman, H.M., Cherikh, W.S., Cheng, Y., Hanto, D.W., Kahan, B.D. Maintenance immunosuppression with target- of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005, 80(7): 883-9.
27. Huang, S., Liu, L.N., Hosoi, H., Dilling, M.B., Shikata, T, Houghton, P.J. p53/p21(CIPl) cooperate in enforcing rapamycin-induced C(l) arrest and determine the cellular response to rapamycin. Cancer Res 2001, 61(8): 3373-81.
28. Neshat, M.S., Mellinghoff, I.K., Tran, C. et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/ mTOR. Proc Natl Acad Sci USA 2001, 98(18): 10314-9.
29. Podsypanina, K., Lee, R.T., Politis, C. et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci USA 2001, 98(18): 10320-5.
30. Garrean, S., Massad, M.G., Tshibaka, M., Hanhan, Z., Caines, A.E., Benedetti, E. Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients. Clin Transplant 2005,19(5): 698-703.
31. Sola, E., Lopez, V., Burgos, D. et al. Pulmonary toxicity associated with sirolimus treatment in kidney transplantation. Transplant Proc 2006 38(8): 2438-40.
32. Rehm, B., Keller, F., Mayer, J., Stracke, S. Resolution of sirolimus-induced pneumonitis after conversion to everolimus. Transplant Proc 2006, 38(3): 711-3.
33. Expósito, V., de Prada, J.A., Góḿez-Roman, J.J. et al. Everolimus-related pulmonary toxicity in heart transplant recipients. J Heart Lung Transplant 2008, 27(7): 797-800.
34. Dutly, A.E., Gaspert, A., Inci, I., Schneiter, D., Korom, S., Weder, W. The influence of the rapamycin-derivate SDZ RAD on the healing of airway anastomoses. Eur J Cardiothorac Surg 2003, 24(1): 154-8; discussion 158.
35. Lorber, M.I., Ponticelli, C, Whelchel, J. et al. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. Clin Transplant 2005,19(2): 145-52.
36. Am Transpl Congr (May 5-9, San Francisco) 2007, Abst 1709.
37. Tedesco-Silva, H. Jr., Vitko, S., Pascual, J. et al.; 2306 and 2307 study groups. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int 2007, 20(1): 27-36.
38. Vazquez de Prada, J.A., Vilchez, F.G., Cobo, M. et al. Sirolimus in de novo heart transplant recipients with severe renal impairment. Transpl Int 2006,19(3): 245-8.
39. Meiser, B., Reichart, B., Adamidis, I., Uberfuhr, P., Kaczmarek, I. First experience with de novo calcineurin- inhibitor-free immunosuppression following cardiac transplantation. Am J Transplant 2005, 5(4 Pt. 1): 827-31.
40. Rothenburger, M., Teerling, E., Bruch, C. et al. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up. J Heart Lung Transplant 2007, 26(3): 250-7.
41. The Organ Procurement and Transplantation Network.
42. Available at: http://www.optn.org. Accessed February 5, 2009.
43. Levy, G.A., Grant, D., Paradis, K., Campestrini, J., Smith, T, Kovarik, J.M. Pharmacokinetics and tolerability of 40-0-[2- hydroxyethyl]rapamycin in de novo liver transplant recipients. Transplantation 2001, 71(1): 160-3.
44. Levy, G., Schmidli, H., Punch, J. et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl 2006,12(11): 1640-1648.
45. Dunkelberg, J.C., Trotter, J.F., Wachs, M. et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl 2003, 9(5): 463-8.
46. Majewski, M., Korecka, M., Joergensen, J. et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003, 75(10): 1710-7.
47. Gomez-Camarero, J., Salcedo, M., Rincon, D. et al. Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation 2007, 84(6): 786-91.
48. Am Transpl Congr (May 5-9, San Francisco) 2007, Abst 1558.
49. Azzola, A., Havryk, A., Chhajed, R et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 2004, 77(2): 275-80.
50. Snell, C.I., Valentine, V.C., Vitulo, P. et al.; RAD B159 Study Group. Everolimus versus azathioprine in maintenance lung transplant recipients: An international, randomized, double blind clinical trial. Am J Transplant 20 06, 6(1): 169-77.
51. Kovarik, J.M., Snell, G.I., Valentine, V.G. et at. Everolimus in pulmonary transplantation: Pharmacokinetics and exposure- response relationships. J Heart Lung Transplant 2006, 25(4): 440-6.
52. Hudes, G., Carducci, M., Tomczak, P. et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356(22): 2271-81.